Investigational drug evaluated in newborns to treat rare disorder

March 21, 2014 by Elizabethe Holland Durando
Investigational drug evaluated in newborns to treat rare disorder
Robert and Sarah Yaroch visit their son Andrew in the neonatal intensive care unit (NICU) at St. Louis Children’s Hospital. Andrew is the third baby worldwide to participate in a clinical trial to treat a rare genetic disorder called X-linked hypohidrotic ectodermal dysplasia (XLHED). Credit: Elizabethe Holland Durando

Children with a rare genetic disorder that causes missing and malformed teeth, sparse hair and the inability to perspire are born without a protein thought to be key to such development.

A clinical trial now underway at Washington University School of Medicine in St. Louis aims to see if the void can be filled with replacement-protein therapy.

Kathy Grange, MD, professor of pediatrics at Washington University, is treating a baby boy with the disorder at St. Louis Children's Hospital. The baby, Andrew Yaroch of Waterford, Mich., is only the third child in the world to receive the drug to treat X-linked hypohidrotic ectodermal dysplasia (XLHED).

The first two infants to participate in the Phase 2 trial received their treatments in California and Germany.

The treatment involves giving EDI200, a replacement protein, to newborn boys found to have mutations in the EDA gene. Individuals with the disease can't produce a protein, ectodysplasin A, that is important in the development of hair, teeth, and exocrine glands such as sweat and salivary glands, which use ducts to secrete their products.

There are currently no treatment options for the disease, other than supportive care.

One of the challenges for investigators is that infants with the disease need to be diagnosed shortly after birth because the intravenous drug treatments are believed to be most effective if begun before the child reaches two weeks of age. The trial calls for a total of five doses of the replacement protein, the first of which is given in the first two weeks of life, and the remaining four doses over about a two-week period.

Only boys are included in the trial because they are afflicted with XLHED more often and more severely than girls. The disorder is caused by a defective gene located on the X chromosome. Females get two copies of the chromosome—one from each parent. So if the XLHED gene is faulty on one X chromosome, the healthy version of the gene on the other chromosome compensates. Males, however, only have one X chromosome, and if the XLHED gene is defective, they inherit the disease.

Andrew was born Feb. 20 in Michigan to Sarah and Robert Yaroch and was quickly diagnosed via genetic testing because of his parents' familiarity with the disease. While Andrew has two older siblings who don't have XLHED, a cousin and his maternal grandfather do.

Investigational drug evaluated in newborns to treat rare disorder
A sign in Andrew’s hospital crib alerts staff and visitors to his inability to sweat. Credit: Elizabethe Holland Durando

The family learned of the clinical trial from Sarah Yaroch's sister, whose 6-year-old son has the disorder. She linked the Yarochs to the National Foundation for Ectodermal Dysplasias, based in Fairview Heights, Ill., and the nonprofit organization connected the family with researchers conducting the trial.

Andrew and his parents flew to St. Louis earlier this month, in time to begin the treatments March 5, at 13 days of age.

"I knew that this was what we needed to do," said Sarah Yaroch. "We knew that this was what was best for him in the long run, whether it has the desired effect or not. My grandkids could have this, my daughter could be a carrier, and it needs to be researched. I feel like we need to help somehow."

Added her husband, Robert Yaroch: "Not everybody has an opportunity to have an impact on the world at large, so I think this is best for Drew, best for our family, best for our extended family—and for other people who could have it in the future and be helped by this."

An international team including then-Washington University researchers David Schlessinger, PhD, and Anand K. Srivastava, PhD, identified the gene for XLHED in the mid-1990s, making research to treat the disorder possible.

Edimer Pharmaceuticals, based in Cambridge, Mass., developed the replacement protein and is funding the trial. Edimer has reported that studies involving XLHED-affected mice and dogs have resulted in permanent corrections regarding some of the disease's manifestations.

The company estimates that worldwide, five in every 100,000 boys are born with the disease. Further, about 50 percent of girls who carry the genetic defect have symptoms that would warrant therapeutic intervention.

XLHED is rare but is one of the most common forms of ectodermal dysplasia.

"Males are much more significantly affected than females," Grange said, explaining why the trial targets newborn boys. "The gene defect they have results in the inability to make a signaling protein that is needed during development of the teeth, hair, sweat glands and other exocrine glands of the body."

People with XLHED are at risk of hyperthermia because of their inability to regulate body temperature. Many also experience recurring respiratory infections.

Those with the disorder also may have eczema, asthma, chronic sinusitis, recurrent nosebleeds and dry eyes. They also typically require significant dental interventions, such as dentures and implants, beginning at a young age.

The researchers believe that the earlier treatment is initiated, the better the outcome may be.

"Maybe in the future the treatment ideally would be given prenatally, but at this point we're trying to give it as early as possible after birth," Grange said.

Explore further: Infants with leukemia inherit susceptibility

Related Stories

Infants with leukemia inherit susceptibility

February 19, 2014
(Medical Xpress)—Babies who develop leukemia during the first year of life appear to have inherited an unfortunate combination of genetic variations that may make the infants highly susceptible to the disease, according ...

Gene therapy for lysosomal storage disease shown to be safe and well tolerated

March 11, 2014
Several young children suffering from a severe degenerative genetic disease received injections of therapeutic genes packaged within a noninfectious viral delivery vector. Safety, tolerability, and efficacy results from this ...

Gene therapy leads to robust improvements in animal model of fatal muscle disease

January 22, 2014
Preclinical studies show that gene therapy can improve muscle strength in small- and large-animal models of a fatal congenital pediatric disease known as X-linked myotubular myopathy. The results, appearing in the Jan. 22 ...

Gene sleuths use social media to help map a new disease

March 21, 2014
(Medical Xpress)—By combining the modern tools of gene-sequencing and social media, a team of researchers has confirmed the identification of a new genetic disorder that causes severe impairments in children.

Compound improves cardiac function in mice with genetic heart defect

February 20, 2014
Congenital heart disease is the most common form of birth defect, affecting one out of every 125 babies, according to the National Institutes of Health. Researchers from the University of Missouri recently found success using ...

Recommended for you

Scientists provide insight into genetic basis of neuropsychiatric disorders

July 21, 2017
A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation ...

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

Late-breaking mutations may play an important role in autism

July 17, 2017
A study of nearly 6,000 families, combining three genetic sequencing technologies, finds that mutations that occur after conception play an important role in autism. A team led by investigators at Boston Children's Hospital ...

Newly discovered gene variants link innate immunity and Alzheimer's disease

July 17, 2017
Three new gene variants, found in a genome wide association study of Alzheimer's disease (AD), point to the brain's immune cells in the onset of the disorder. These genes encode three proteins that are found in microglia, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.